Urogen pharma announces inducement grants under nasdaq listing rule 5635(c)(4)

Princeton, n.j.--(business wire)--urogen pharma ltd. (nasdaq: urgn), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“rsus”) and an option (“option”) to 15 new employees in connection with their employment with urogen. these new team members will support the ongoing commercialization of jelmyto® (mitomycin) for pyelocalyceal solution, urogen's first ap.
NDAQ Ratings Summary
NDAQ Quant Ranking